Fox News senior medical analyst Dr. Marc Siegel has the latest on the discounted products under President Donald Trump’s plan on ‘The Bottom Line.’
EXCLUSIVE: The White House is expecting to announce an expansion of drugmakers offering discounts on TrumpRx.gov, FOX Business has learned.
As early as today, Amgen and GSK will be added to the list of prescription drug manufacturers offering discounts on the government website. That makes a total of 54 prescription medications from six pharmaceutical companies that have signed on to the most-favored-nation pricing under pressure from President Donald Trump and the threat of tariffs.
Advertisement
Amgen will offer medication on the website that cuts 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis.
President Donald Trump speaks as Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz looks on during an event on drug pricing in the South Court Auditorium on the White House campus Feb. 5, 2026, in Washington, D.C. (Nathan Howard/Getty Images)
The company plans to list Aimovig and Repatha for discounts of 62%.
GSK will discount Incruse at 55% of the retail price. The drug treats COPD and will be listed at $159.
Advertisement
GSK also plans to list Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%.
“GSK and Amgen connecting with TrumpRx.gov to offer prescription drugs directly to consumers at most-favored-nations pricing marks another milestone for President Trump’s affordability push,” White House spokesman Kush Desai told FOX Business.
“TrumpRx.gov is just the beginning, however, as Americans are set to (receive) even greater drug pricing discounts, lower insurance premiums and more transparency when Congress passes President Trump’s Great Healthcare Plan.”
Amgen will offer medication on the website that cuts 80% off the retail price. (George Frey/Bloomberg via Getty Images)
The Pharmaceutical Research and Manufacturers of America represents major drug companies.
Advertisement
CEO Stephen Ubl believes “Government-imposed most-favored-nation policies would undermine U.S. competitiveness while doing nothing to address insurance practices that deny care and raise costs for patients.
Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.
Cryptocurrency staking is a way for people to help maintain a blockchain network and potentially earn rewards for doing so. Staking plays a crucial role in how transactions
I’ve been researching companies in-depth for over a decade, from commodities like oil, natural gas, gold and copper to tech like Google or Nokia and many emerging market stocks, which I believe could help me provide useful content for readers. After writing my own blog for about 3 years, I decided to switch to a value investing-focused YouTube channel, where I researched hundreds of different companies so far. I would say my favorite type of company to cover are metals and mining stocks, but I am comfortable with several other industries, such as consumer discretionary/staples, REITs and utilities.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CUBE over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Those who have been waiting for Randy Orton to turn heel, the term used for villains in the WWE, got what they have been waiting for.
On the March 13 edition of Friday Night SmackDown, Orton turned heel and viciously attacked Cody Rhodes.
Randy Orton Turns Heel
The heel turn took place during the contract signing between Orton and Rhodes. The two WWE superstars are set to compete in a match for the Undisputed WWE Championship at WrestleMania 42 next month.
While initially looking like they were to remain friends despite going against one another, Orton soon changed his tune and attacked Rhodes.
Orton hit his old friend with the steel steps at some point, busting the latter wide open. While officials came out to try and control the situation, Orton eventually had the opportunity to hit Rhodes with the steel chair while his head was lying against the steel steps.
Advertisement
Will Orton Get His 15th World Championship?
Ever since it became clear that it would be Rhodes versus Orton for WrestleMania 42, fans have been speculating which of the two will turn heel.
Leading up to the March 13 edition of SmackDown, both characters have been faces, the term used for the good guys in wrestling.
It should be noted that despite the vicious attack, the live crowd was clearly behind Orton, chanting his name despite him clearly becoming the bad guy.
Should Orton win at WrestleMania 42, it will be his 15th world championship with WWE. He’s currently tied at 14 world title reigns with Paul “Triple H” Levesque.
Get ready for an exciting investment opportunity! Muthoot FinCorp is rolling out a bond issue, aiming to gather as much as ₹600 crore to bolster business expansion and fulfill corporate goals. With appealing yields and flexible tenure options, these bonds are perfect for retail investors looking to dive in before March 23.
The base issue size is ₹200 crore, with a greenshoe option to retain oversubscription of up to ₹400 crore, the company said. “This offering is intended to support onward lending and financing activities, repay/prepay interest and principal on existing debt, and meet general corporate needs,” the company said.
Live Events
The bonds are rated ‘AA-/positive’ by Crisil Ratings and ‘AA/stable’ by Brickwork Ratings India, indicating a high degree of safety for the timely servicing of financial obligations. Muthoot FinCorp, which is not publicly listed, had standalone assets under management of ₹48,122 crore at the end of December, up 63% from the same period a year earlier, driven largely by demand for gold loans.
KLA Corporation (KLAC) Analyst/Investor Day March 12, 2026 9:00 AM EDT
Company Participants
Bren Higgins – Executive VP & CFO Richard Wallace – President, CEO & Executive Director Ahmad Khan – President of Semiconductor Products & Customers Brian Lorig – Executive Vice President of KLA Global Services
Conference Call Participants
Advertisement
Atif Malik – Citigroup Inc., Research Division Stacy Rasgon – Bernstein Institutional Services LLC, Research Division Joseph Quatrochi – Wells Fargo Securities, LLC, Research Division Christopher Caso – Wolfe Research, LLC Harlan Sur – JPMorgan Chase & Co, Research Division Sreekrishnan Sankarnarayanan – TD Cowen, Research Division Vivek Arya – BofA Securities, Research Division Christopher Muse – Cantor Fitzgerald & Co., Research Division Shane Brett – Morgan Stanley, Research Division Yu Shi – Needham & Company, LLC, Research Division Melissa Weathers – Deutsche Bank AG, Research Division
Presentation
Unknown Attendee
Advertisement
Please welcome KLA EVP, CFO and Global Operations, Bren Higgins.
Bren Higgins Executive VP & CFO
Good morning. Thank you for being here for our 2026 KLA Investor Day. It’s great to be back in New York. I’m going to make a few comments. First, I’m going to walk through the agenda overall. So I’ll make a few comments, and then I’ll transition to our President and CEO, Rick Wallace, who will talk about compounding sustainable outperformance of the company, where we’ve been and where we’re going, some of the dynamics that are driving the ecosystem and how that plays through to opportunities for KLA relevance.
Advertisement
Ahmad Khan, who’s the President of our Semiconductor Products and Customers business, will then stand up and talk about process control in the AI era, some of the dynamics that are driving our business, how we’re collaborating and engaging with customers that drives our innovation model and ultimately, how we execute. And our strategy is to take advantage of what looks like a very exciting business environment moving forward.
As grain farmers prepare for spring planting, any optimism for the coming season is being tempered by the economic reality that they may face another money-losing year. This was looking to be the case even before the conflict began in Iran, which triggered a surge in fertilizer prices.
Input costs skyrocketed in 2022 after the start of the Russia-Ukraine war and remain elevated, while commodity prices sit under production costs. The American Farm Bureau says many row-crop farmers are looking at four or five straight years of operational losses, even after accounting for crop insurance payments and ad-hoc assistance.
Advertisement
Philip Nelson, a fourth-generation farmer in LaSalle County, Illinois, who was recently elected as Illinois Farm Bureau president, says the profits farmers made when crop prices were high a few years ago have eroded and balance sheets are tight.
“If you adjust for inflation, we’ve got the same commodity prices we had in 1974, and at the same time, the input costs have quadrupled,” Nelson says.
Input costs aren’t the only issue clouding farmers’ outlooks for spring planting. Last year, the U.S. harvested a record corn crop of roughly 18 billion bushels, and that heavy supply continues to weigh on the market, says Sean Lusk, vice president, commercial hedging division for Walsh Trading. In addition, the outlook for soybeans remains mixed as farmers wait on the Trump administration to decide on a potential expansion of the biomass-based diesel program that could offset some of the lost export market share to China amid recent trade tensions.
In a challenging year, risk management tools and fine-tuning marketing plans take on added importance.
Advertisement
Shifting Farmer Sentiment
The Purdue University-CME Group Ag Economy Barometer weakened in December, reflecting farmers’ declining long-term outlook about U.S. soybean export prospects as competition from Brazil increases. More recently, the focus has shifted to tensions between current conditions and future expectations, with farmers more optimistic about the former than the latter.
The U.S. Department of Agriculture’s (USDA) Economic Research Service forecasts net farm income to fall by 2.6% year-over-year in inflation-adjusted terms. The decline is mitigated in part by the Farmer Bridge Assistance Program and the Emergency Commodity Assistance Program, USDA’s aid packages for farmers to offset losses because of the trade environment. However, the American Farm Bureau says most producers likely will still lose money.
University of Illinois agricultural researchers forecast crop prices to be marginally higher in 2026. As of early March, CME Group September 2026 Corn and Soybean futures are trading around $4.55 and $11.32 per bushel, respectively.
Price gains compared to last year will likely be offset by small increases in overall costs with yields at trend levels. Break-even prices to cover all costs without government support are in the $4.70-$4.90 range for corn and $10.80-$11.25 range for soybeans, close to or above current market prices and pricing opportunities for the 2026 crop.
Advertisement
David Iserman, a fifth-generation farmer based in Streator, Illinois, is sanguine about the growing season, based on those figures. “We’re definitely either breaking even, if we’re lucky, or losing money,” he says.
Cost-Cutting Measures
Annual inputs, such as seed, fertilizer and chemicals, are higher than last year. Corn consumes more inputs than soybeans, and that may factor into what U.S. farmers plant this spring – though markets won’t know for sure until the 2026 Prospective Plantings report is released on March 31. However, many farmers typically still stick with a traditional 50/50 corn and soybean rotation for agronomic reasons, which is what Iserman and Nelson plan to do.
Both producers have experienced lean times before and are looking at ways to cut costs. Iserman says fertilizer is his number one cost. He practices no-till farming on his soybeans and strip-till for corn. In strip-till farming, producers till a narrow strip of soil for fertilizer on the corn, which minimizes loss.
Iserman may tweak how much he uses and is studying the cost, using software to gauge his returns on his fertilizer use.
Advertisement
“We’re looking at all of our fertilizer inputs from the standpoint of not yield, but profit. For every dollar I put in, I want to get $1 back. I don’t care about winning a yield contest. I care about return,” he says.
Nelson also says he might cut back slightly on fertilizer use because he has built it up in the soil, giving him an option to cut costs.
Fertilizer Prices Stay High
Fertilizer remains the most volatile and significant non-land cost, often accounting for 20% to 30% of total production expenses, according to USDA data.
Josh Linville, vice president of fertilizer at StoneX, says prices remain significantly higher than a year ago. In early 2026, a barge of urea at the port of New Orleans traded around $450 per ton, compared to $389 per ton in early 2025. Nitrogen prices are also higher versus a year ago.
Advertisement
Three global factors drive this inflation, Linville says. China, a major global supplier, has indicated it may not export urea until August 2026, removing millions of tons from the global market. In Europe, persistent high natural gas costs have limited nitrogen production to about 75% of normal since the second half of 2022 because of the Russia-Ukraine war. In the Middle East, the Strait of Hormuz is a critical choke point through which three of the top 10 urea exporters must ship their product. As of early March, the Strait of Hormuz is facing a blockade.
To better understand fertilizer costs, some farmers look at the corn-urea and soybean-urea ratio. These ratios position fertilizer costs within the context of crop costs, calculating how many bushels of grain are required to purchase one ton of nutrients.
A lower ratio signals a more favorable time to lock in costs. Currently, with low corn prices and high urea prices, the corn-urea ratio sits near 87 to 90 bushels per ton, a five-year high. To manage this, some farmers are using CME Group’s 10-Ton Urea U.S. Gulf futures contract. Launched last year, this tool allows individual producers to hedge their fertilizer risk in increments more suited to their actual field needs, and options can help limit price risk to the upside. While fertilizer costs were elevated in January, those levels now appear relatively attractive by comparison.
A Changing Approach
“Frankly speaking, we don’t sell all of our grain in one decision. We should be looking at doing the same thing with fertilizer,” Linville says.
Advertisement
He notes that traditionally farmers have looked at their fertilizer purchases annually, but watching prices throughout the year may help them make smarter operational decisions.
Farmers interested in adding the fertilizer ratios as part of their risk management toolkit can start by talking to their local grain elevator, which may give them data stretching back a few years to help them plot trends, he says. With this information, farmers may be able to act on price changes and lock in better prices.
